Latest Articles
Endometrial cancer, Campagnoli (GSK): "Immunotherapy increases overall survival." - lamilano.it
Endometrial cancer, Campagnoli (GSK): "Immunotherapy increases overall survival." lamilano.it
Published: Feb. 23, 2026, 5:15 p.m.
Overall Survival After Hormonal Therapy vs Hysterectomy in Early Endometrial Cancer - The ASCO Post
Overall Survival After Hormonal Therapy vs Hysterectomy in Early Endometrial Cancer The ASCO Post
Published: Sept. 19, 2025, 2:31 p.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …
Published: April 18, 2025, 5:25 a.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …
Published: April 18, 2025, 12:16 a.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …
Published: April 17, 2025, 5:15 p.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …
Published: April 17, 2025, 5:15 p.m.
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma - MedPage Today
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma MedPage Today
Published: April 9, 2025, 3:15 p.m.
Establishment and validation of a prognostic nomogram for overall survival in type II endometrial carcinoma patients - Nature.com
Establishment and validation of a prognostic nomogram for overall survival in type II endometrial carcinoma patients Nature.com
Published: March 6, 2025, 6:11 a.m.
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com
Published: March 5, 2025, 11:04 a.m.
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy - The ASCO Post
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy The ASCO Post
Published: March 27, 2024, 6:45 p.m.
Link copied to clipboard!